SCHEMBL20489672

SCHEMBL20489672

COCc1nc2nc(SC)sc2c(=O)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 2/20 0.42
HCAR2 Q8TDS4 1/20 0.36
PKM P14618 2/20 0.35
KDR P35968 1/20 0.35
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CXCR1 P25024 1/20 0.33
CXCR2 P25025 1/20 0.33
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CDC7 O00311 1/20 0.31
ROCK1 Q13464 1/20 0.31
DBF4 Q9UBU7 1/20 0.31
USP2 O75604 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489585 0.86 KDR (0.33) SMN1; SMN2ALDH1A1KDRCXCR1CXCR2
SCHEMBL20489502 0.75 KDR (0.40) SMN1; SMN2ALDH1A1KDRCCNE1CDK2
SCHEMBL20489427 0.71 KDR (0.36) HCAR2KDRCXCR1CXCR2
SCHEMBL20489472 0.71 PIM1 (0.40) SMN1; SMN2ALDH1A1HCAR2PKMKDR
SCHEMBL21206764 0.69 KDR (0.51) SMN1; SMN2KDR
SCHEMBL21206707 0.69 KDR (0.37) KDR
SCHEMBL21206624 0.66 AADAT (0.39) KDR
SCHEMBL21206742 0.66 KDR (0.35) KDR
SCHEMBL4478360 0.65 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KDRCDK2CDC7
SCHEMBL21206717 0.65 AADAT (0.37) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3372601-B1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2022-09-21 EP disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
EP-3372601-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2018-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND KAT2A, KAT7, KAT5 SMN1; SMN2 4513/4885ALDH1A1 2879/4885HCAR2 1517/4885
US-10793582-B2 Bicyclic heterocyclic compound KAT2A, KAT7, KAT5 SMN1; SMN2 4455/4885ALDH1A1 2375/4885HCAR2 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.